Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Watchlist
Price: 400.17 USD 0.63% Market Closed
Market Cap: 52.9B USD

Operating Margin
Alnylam Pharmaceuticals Inc

8.3%
Current
-28%
Average
-4.3%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
8.3%
=
Operating Profit
264.7m
/
Revenue
3.2B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD
8%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
405.3B USD
33%
US
Amgen Inc
NASDAQ:AMGN
176.3B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
151B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.7B USD
28%
AU
CSL Ltd
ASX:CSL
83.5B AUD
26%
NL
argenx SE
XBRU:ARGX
43.5B EUR
22%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
No Stocks Found

Alnylam Pharmaceuticals Inc
Glance View

In the heart of the biotechnology revolution, Alnylam Pharmaceuticals Inc. has been a pioneering force, transforming the landscape of medicine through its innovative use of RNA interference (RNAi) technology. Founded in 2002 and based in Cambridge, Massachusetts, the company set out on a bold mission to silence disease-causing genes by targeting RNA, the intermediary that carries genetic instructions necessary for protein synthesis. This groundbreaking approach diverges from traditional methods that focus on targeting proteins directly and instead intervenes earlier in the disease process to eliminate or reduce the proteins before they can wreak havoc on the body. Fueled by extensive research and a robust pipeline, Alnylam has successfully brought several RNAi-based therapies to market, such as Onpattro and Givlaari, which address rare genetic disorders with high unmet medical needs. Alnylam's business model is centered around the commercial success of its novel therapies, partnerships with other pharmaceutical giants, and strategic collaborations for global distribution. By securing alliances with industry leaders like Sanofi and Regeneron, Alnylam has been able to expand its research capabilities and broaden its market reach. Revenue for the company is primarily driven by the sales of its approved products, which continue to grow as they gain acceptance within the medical community. Additionally, Alnylam's extensive patent portfolio and its strategic licensing agreements provide an additional revenue stream, safeguarding its innovations and ensuring it retains a competitive edge in this rapidly advancing field. Through its relentless pursuit of innovation, Alnylam continues to position itself as a trailblazer in turning the once theoretical promise of RNAi into a clinical reality.

ALNY Intrinsic Value
298.7 USD
Overvaluation 25%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
8.3%
=
Operating Profit
264.7m
/
Revenue
3.2B
What is the Operating Margin of Alnylam Pharmaceuticals Inc?

Based on Alnylam Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of 8.3%.

Back to Top